Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
=== Transport === Like most of northwest London, Brent is served extensively by the London Underground. 21 tube stations are located in Brent, all served by either the Metropolitan, Jubilee, Bakerloo or Piccadilly Lines. All of them are surface level, with the exception of Kilburn Park tube station in the southeast of the borough. This number is the second highest of all London boroughs behind Westminster, which has 32 stations within its boundaries. The numerous London Underground, London Overground and National Rail stations in the borough are:
=== Conductors === According to Gauss’s law, a conductor at equilibrium carrying an applied current has no charge on its interior. Instead, the entirety of the charge of the conductor resides on the surface, and can be expressed by the equation:
In fact, the aggregation of a protein generates a variety of aggregates, all of which are likely to be toxic to some degree. A wide variety of biochemical, physiological and cytological perturbations has been identified following the exposure of cells and animals to such species, independently of their identity. The oligomers have also been reported to interact with a variety of molecular targets. Hence, it is unlikely that there is a unique mechanism of toxicity or a unique cascade of cellular events. The misfolded nature of protein aggregates causes a multitude of aberrant interactions with a multitude of cellular components, including membranes, protein receptors, soluble proteins, RNAs, small metabolites, etc.
The United States was the biggest foreign investment source and one of Malaysia's closest allies during Mahathir's rule. A 2003 house hearing by the Subcommittee on East Asia and the Pacific of the U.S. House International Relations Committee (now called the House Committee on Foreign Affairs) summarises the relationship between the United States and Malaysia as follows: "Despite sometimes blunt and intemperate public remarks by Prime Minister Mahathir, U.S.-Malaysian cooperation has a solid record in areas as diverse as education, trade, military relations, and counter-terrorism." Mahathir was publicly critical of the foreign policy of the United States, particularly during George W. Bush's presidency. He has also condemned the US-led war on Iraq and Afghanistan. In 1984, during his first visit to the United States, Mahathir received a warm welcome. He met President Ronald Reagan in the Oval Office, followed by discussions, lunch, and a press conference. He also made a private visit to Tulsa, Oklahoma. Reagan said he and Mahathir "had a valuable exchange of views on international and bilateral issues and found ourselves in agreement to a remarkable degree", but acknowledged differences in Middle East policy. In the years that followed, Mahathir held informal meetings with US presidents George H. W. Bush, Bill Clinton, and George W. Bush at various locations to discuss issues related to palm oil and the United States' attitude towards Muslim countries. In January 1997, Mahathir visited the United States to promote Malaysia's Multimedia Super Corridor.
Sources: en.wikipedia.org
In October 2023, the US Food and Drug Administration (FDA) approved Vamorolone (Agamree) as a Treatment for Duchenne muscular dystrophy. Catalyst Pharmaceuticals holds the exclusive North American license and commercial rights. In March 2024, the FDA approved givinostat (Duvyzat), an oral medication, to be used in the treatment of Duchenne muscular dystrophy in people aged six years and older. Givinostat is the first nonsteroidal drug to receive FDA approval for the treatment of all genetic variants of Duchenne muscular dystrophy. Functioning as a histone deacetylase (histone deacetylase (HDAC) inhibitor, givinostat operates by targeting pathogenic processes within the body, ultimately leading to a reduction in inflammation and muscle loss associated with the disease.
1993/764) Value Added Tax (Increase of Consideration for Fuel) Order 1993 (S.I. 1993/765) Value Added Tax (Increase of Registration Limits) Order 1993 (S.I. 1993/766) Value Added Tax (Protective Boots and Helmets) Order 1993 (S.I. 1993/767) Registered Establishments (Fees) (Scotland) Order 1993 (S.I. 1993/768) Act of Sederunt (Interest in Sheriff Court Decrees and Extracts) 1993 (S.I. 1993/769) Act of Sederunt (Rules of the Court of Session Amendment) (Interest in Decrees and Extracts) 1993 (S.I. 1993/770) Water Undertakers (Rateable Values) (Amendment) Order 1993 (S.I. 1993/772) Council Tax (Administration and Enforcement) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/773) Non-Domestic Rating (Collection and Enforcement) (Amendment and Miscellaneous Provision) Regulations 1993 (S.I. 1993/774) Community Charges (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/775) Pensions Increase (Review) Order 1993 (S.I. 1993/779) British Railways (Penalty Fares) Act 1989 (Activating No. 9) Order 1993 (S.I. 1993/780) British Railways (Penalty Fares) Act 1989 (Activating No. 10) Order 1993 (S.I. 1993/781) Premium Savings Bonds (Amendment) Regulations 1993 (S.I. 1993/782) National Savings Stock Register (Amendment) Regulations 1993 (S.I. 1993/783) Redundancy Payments (Local Government) (Modification) (Amendment) Order 1993 (S.I. 1993/784) Child Support Act 1991 (Consequential Amendments) Order 1993 (S.I. 1993/785) Chester Port Health Authority (Revocation)Order 1993 (S.I. 1993/786) Civil Legal Aid (Assessment of Resources) (Amendment) Regulations 1993 (S.I.
Amanita virosa first appears as a white, egg-shaped object covered with a universal veil. As it expands, the mushroom-shaped fruit body breaks free, though ragged patches of veil may persist at the cap edges. The cap is initially conical with inturned edges, before becoming hemispherical and flattening with a diameter up to 12 cm (4+3⁄4 in). The cap often has a distinctive boss; it is able to be peeled and is white, though the centre may be ivory. The crowded, free gills are white, as is the stipe and volva. The thin stipe is up to 15 cm (5.9 in) tall, with a hanging, grooved ring. The spore print is white and the spores are subglobose and 7–10 μm long. They are amyloid, staining purple with Melzer's reagent. The flesh is white, with a smell reminiscent of radishes, and turns bright yellow with sodium hydroxide.
Sources: en.wikipedia.org
=== China === It is possible that black pepper was known in China in the second century BCE, if poetic reports regarding an explorer named Tang Meng (唐蒙) are correct. Sent by Emperor Wu to what is now south-west China, Tang Meng is said to have come across something called jujiang or "sauce-betel". He was told it came from the markets of Shu, an area in what is now the Sichuan province. The traditional view among historians is that "sauce-betel" is a sauce made from betel leaves, but arguments have been made that it actually refers to pepper, either long or black.
Criminologist Jane Monkton-Smith said it was particularly unusual that Norris didn't behave as if he wanted to defend himself in interviews, but instead challenged the police and acted evasively. Norris later admitted that he was trying to show how much more he knew than the police in interviews. In 2004, during the investigation, he walked into the offices of the Yorkshire Evening Post and declared that the police had "nothing on him" to reporters. Chief superintendent on the case Chris Gregg claimed that Norris's prediction of Hall's illness showed that it wasn't just a spontaneous incident where a criminal nurse at work had, for whatever reason decided to kill someone, saying "he actually premeditated this, hours before". Gregg said: "I think he was cocky; I think he was over-confident. He was showing off". A criminal psychologist stated that, despite Norris's prediction, it was unlikely that he wanted to get caught, rather that he merely wanted to demonstrate a sense of superior knowledge. Police noted that, in interviews, Norris showed no empathy for the women who had died or for their families, and claimed he couldn't remember any of the women.
=== Chemical synthesis === The chemical synthesis is similar to the biosynthesis, starting from the unsaturated compound without a cyclopropane ring, the vaccenic acid. In a Simmons-Smith reaction, a carbene is added to the double bond of the unsaturated fatty acid; diiodomethane and zinc are used to form the carbene. The Simmons-Smith reaction is stereospecific, for the preparation of cis-11,12-methylenoctadecenoic acid (lactobacillic acid) the cis-11-octadecenoic acid (cis-vaccenoic acid) is used. This can be of natural origin or synthesized from 11-octadecic acid.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.